查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813840

美国过敏和自体免疫疾病诊断市场规模、份额和趋势分析（按产品/服务、测试类型、诊断类型、最终用途和细分市场），2025 年至 2033 年

U.S. Allergy And Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Product & Services (Allergy Diagnostics, Autoimmune Disease), By Test Type, By Diagnostics Type, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

美国过敏和自体免疫疾病诊断市场预计在 2024 年价值 40.3 亿美元，预计到 2033 年将达到 84 亿美元，2025 年至 2033 年的复合年增长率为 8.67%。

这一市场的主要驱动因素包括过敏和自体免疫疾病的盛行率上升、患者意识的增强以及专业诊断检测的普及。过敏诊断广泛应用于识别特异性IgE介导的反应，而自体免疫疾病诊断则支持类风湿性关节炎、全身性红斑性狼疮和多发性硬化症等复杂疾病的早期发现和鑑别诊断。

此外，随着过敏和自体免疫疾病诊断检测量的不断增加，样本处理、检测通量和数据报告也需要显着改善。这些改进有助于提高实验室营运效率，并扩大专业检测的覆盖范围。越来越多的实验室采用自动化和整合平台来管理日益增长的需求、简化工作流程，并维持日益复杂的检测的准确性。

数位化报告系统及其与电子健康记录的连结进一步改善了诊断团队和临床医生之间的协作。这些工具缩短了周转时间，并支持在慢性过敏和自体免疫疾病的管理中及时做出临床决策。

美国市场正经历由研发驱动的持续创新，并转向更具针对性的诊断解决方案。 2025年4月，贝克曼库尔特生命科学公司推出了新一代嗜碱性粒细胞活化检测 (BAT)，以支持过敏研究。虽然该检测专为研究用途而设计，但它反映出人们越来越重视功能性检测，以便更深入地了解免疫细胞行为和过敏诱因。

与之相关的一项进展是，Well Theory 于 2023 年 10 月宣布推出一项企业解决方案，旨在透过雇主和付款人网路解决自体免疫的护理问题。该平台专注于系统化、基于生活方式的自体免疫疾病管理，凸显了将诊断与持续患者支持相结合的市场趋势。此类努力反映出，诊断与照护服务模式日益融合，旨在改善慢性免疫疾病患者的长期预后。

美国市场正朝着更专业、数据主导的模式发展，将诊断与个人化照护紧密结合。随着检测技术日益成熟和普及，预计市场将受益于临床整合的增强、病人参与的提升，以及在传统医疗机构和新兴医疗平台的广泛应用。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章美国过敏和自体免疫疾病诊断市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国过敏与自体免疫疾病诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国过敏和自体免疫疾病诊断市场：产品和服务估计和趋势分析

  • 2024 年和 2033 年产品和服务市场份额
  • 细分仪表板
  • 美国过敏和自体免疫疾病诊断市场：产品和服务展望
  • 过敏诊断
    • 装置
    • 耗材
    • 服务
  • 自体免疫疾病的诊断
    • 装置
    • 耗材
    • 服务

第五章美国过敏和自体免疫疾病诊断市场：测试类型估计和趋势分析

  • 2024 年和 2033 年测试类型市场份额
  • 细分仪表板
  • 美国过敏和自体免疫疾病诊断市场：按测试类型分類的展望
  • 过敏诊断
    • 体内测试
  • 自体免疫疾病的诊断
    • 抗核抗体检测
    • 自体抗体检测
    • C反应蛋白（CRP）
    • 全血球计数（CBC）
    • 尿液检查
    • 其他的

第六章美国过敏和自体免疫疾病诊断市场：诊断类型估计和趋势分析

  • 2024 年和 2033 年诊断类型市场份额
  • 细分仪表板
  • 美国过敏与自体免疫疾病诊断市场：按诊断类型分類的展望
  • 过敏诊断
    • 食物
    • 吸入
    • 药品
    • 其他过敏原
  • 自体免疫疾病
    • 系统性自体免疫疾病的诊断
    • 局部自体免疫疾病诊断

第七章美国过敏和自体免疫疾病诊断市场：最终用途估计和趋势分析

  • 2024年和2033年的最终用途市场份额
  • 细分仪表板
  • 过敏和自体免疫疾病诊断市场：最终用途差异分析
  • 过敏诊断
    • 医院和诊所
    • 诊断实验室
    • 研究机构
    • 其他的
  • 自体免疫诊断
    • 医院和诊所
    • 诊断实验室
    • 研究机构
    • 其他的

第八章 竞争态势

  • 公司分类
  • 战略地图
    • 推出新产品和服务
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 2024年主要企业市占率分析
  • 公司热图分析
  • 公司简介
    • Thermo Fisher Scientific, Inc.
    • HYCOR Biomedical
    • EUROIMMUN Medizinische Labordiagnostika AG（PerkinElmer）
    • Omega Diagnostics GROUP PLC
    • Lincoln Diagnostics, Inc.
    • AESKU.GROUP GmbH
    • Minaris Medical America, Inc.
    • HOB Biotech Group Corp., Ltd.
    • DASIT Group SPA
    • R-Biopharm AG
    • BIOMERIEUX
    • Siemens Healthcare GmbH
    • Hoffmann-La Roche Ltd
    • Abbott
    • Beckman Coulter, Inc.
    • Danaher Corporation
    • Quest Diagnostics
    • Nova Diagnostics Pte Ltd.
Product Code: GVR-4-68040-695-1

Market Size & Trends:

The U.S. allergy and autoimmune disease diagnostics market size was estimated at USD 4.03 billion in 2024 and is projected to reach USD 8.40 billion by 2033, growing at a CAGR of 8.67% from 2025 to 2033. The market is primarily driven by the rising incidence of allergic and autoimmune disorders, increasing patient awareness, and improved access to specialized diagnostic testing. Allergy diagnostics are widely used to identify specific IgE-mediated reactions, while autoimmune disease diagnostics support early detection and differentiation of complex conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

In addition, the growing volume of diagnostic testing for allergy and autoimmune conditions has prompted significant improvements in sample handling, assay throughput, and data reporting. These enhancements support more efficient laboratory operations and expand access to specialized tests. Laboratories are increasingly adopting automation and integrated platforms to manage rising demand, streamline workflows, and maintain accuracy in high-complexity testing.

Digitized reporting systems and connectivity with electronic health records further improve coordination between diagnostic teams and clinicians. These tools reduce turnaround times and support timely clinical decision-making in managing chronic allergic and autoimmune conditions.

The U.S. market is experiencing continuous innovation, driven by research-focused developments and a shift toward more targeted diagnostic solutions. In April 2025, Beckman Coulter Life Sciences introduced its Next-Generation Basophil Activation Test (BAT) to support allergy research. Although designed for research use only, the test reflects a growing emphasis on functional assays that offer deeper insights into immune cell behavior and allergic triggers.

In a related development, WellTheory launched an enterprise solution in October 2023 to address autoimmune care through employer and payer networks. This platform focuses on structured, lifestyle-based management of autoimmune symptoms, underscoring a broader market trend toward integrating diagnostics with ongoing patient support. These efforts reflect how diagnostics are increasingly paired with care delivery models to improve long-term outcomes for individuals with chronic immune conditions.

The U.S. market is evolving toward more specialized, data-driven approaches that align diagnostics with personalized care. As testing technologies become more sophisticated and accessible, the market is expected to benefit from stronger clinical integration, improved patient engagement, and broader adoption across traditional healthcare settings and emerging care platforms.

U.S. Allergy And Autoimmune Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. allergy and autoimmune disease diagnostics market report based on products & services, diagnostic type, test type, and end use:

  • Products & Services Outlook (Revenue in USD Million, 2021 - 2033)
  • Allergy Diagnostics
    • Instruments
    • Consumables
    • Services
  • Autoimmune Disease Diagnostics
    • Instruments
    • Consumables
    • Services
  • Test Type Outlook (Revenue in USD Million, 2021 - 2033)
  • Allergy Diagnostics
    • In vivo Test
    • Skin Prick Test
    • Intradermal Test
    • Patch Test
    • In vitro Test
  • Autoimmune Disease Diagnostics
    • Antinuclear Antibody Tests
    • Autoantibody Tests
    • C-reactive Protein (CRP)
    • Complete Blood Count (CBC)
    • Urinalysis
    • Others
  • Diagnostics Type Outlook (Revenue in USD Million, 2021 - 2033)
  • Allergy Diagnostics
    • Food
    • Dairy Products
    • Poultry Product
    • Tree Nuts
    • Peanuts
    • Shellfish
    • Wheat
    • Soys
    • Other Food Allergens
    • Inhaled
    • Drug
    • Other Allergens
  • Autoimmune Disease Diagnostics
    • Systemic Autoimmune Disease Diagnostics
    • Rheumatoid Arthritis
    • Ankylosing Spondylitis
    • Systemic Lupus Erythematosus (SLE)
    • Others
    • Localized Autoimmune Disease Diagnostics
    • Multiple Sclerosis
    • Type 1 Diabetes
    • Hashimoto's Thyroiditis
    • Idiopathic Thrombocytopenic Purpura
    • Others
  • End Use Outlook (Revenue in USD Million, 2021 - 2033)
  • Allergy Diagnostics
    • Hospitals & Clinics
    • Diagnostics Laboratories
    • Research Institutions
    • Others
  • Autoimmune Disease
    • Hospitals & Clinics
    • Diagnostics Laboratories
    • Research Institutions
    • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Products and Services
    • 1.2.2. Test Type
    • 1.2.3. Diagnostic Type
    • 1.2.4. End Use
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Products and Services and Test type Snapshot
    • 2.2.2. Diagnostics Type Snapshot
    • 2.2.3. End Use Snapshot
  • 2.3. Competitive Insights

Chapter 3. U.S. Allergy and Autoimmune Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Immune-Related Disorders
      • 3.2.1.2. Shift Toward Early and Personalized Diagnosis
      • 3.2.1.3. Expansion of Decentralized and Home-Based Testing
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Advanced Diagnostic Technologies
      • 3.2.2.2. Underdiagnosis and Limited Awareness in Emerging Markets
      • 3.2.2.3. Regulatory and Reimbursement Barriers
  • 3.3. U.S. Allergy And Autoimmune Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Allergy And Autoimmune Disease Diagnostics Market: Products and Services Estimates & Trend Analysis

  • 4.1. Products and Services Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. U.S. Allergy And Autoimmune Disease Diagnostics Market, by Products and Services Outlook
  • 4.4. Allergy Diagnostics
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Consumables
      • 4.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Services
      • 4.4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Autoimmune Disease Diagnostics
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Instruments
      • 4.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Consumables
      • 4.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Services
      • 4.5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Allergy And Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Test Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Allergy And Autoimmune Disease Diagnostics Market by Test Type Outlook
  • 5.4. Allergy Diagnostics
    • 5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. In vivo Test
      • 5.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.2. Skin Prick Test
        • 5.4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.3. Intradermal Test
        • 5.4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.4. Patch Test
        • 5.4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.5. In vitro Test
        • 5.4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Autoimmune Disease Diagnostics
    • 5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Antinuclear Antibody Tests
      • 5.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Autoantibody Tests
      • 5.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. C-reactive Protein (CRP)
      • 5.5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Complete Blood Count (CBC)
      • 5.5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.6. Urinalysis
      • 5.5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.7. Others
      • 5.5.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Allergy And Autoimmune Disease Diagnostics Market: Diagnostics Type Estimates & Trend Analysis

  • 6.1. Diagnostics Type Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. U.S. Allergy And Autoimmune Disease Diagnostics Market by Diagnostics Type Outlook
  • 6.4. Allergy Diagnostics
    • 6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Food
      • 6.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.2. Dairy Products
        • 6.4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.3. Poultry Product
        • 6.4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.4. Tree Nuts
        • 6.4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.5. Peanuts
        • 6.4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.6. Shellfish
        • 6.4.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.7. Wheat
        • 6.4.2.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.8. Soys
        • 6.4.2.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.9. Other Food Allergens
        • 6.4.2.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Inhale
      • 6.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Drug
      • 6.4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Other allergens
      • 6.4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Autoimmune Disease
    • 6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Systemic Autoimmune Disease Diagnostics
      • 6.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.2.2. Rheumatoid Arthritis
        • 6.5.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.2.3. Ankylosing Spondylitis
        • 6.5.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.2.4. Systemic Lupus Erythematosus (SLE)
        • 6.5.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.2.5. Others
        • 6.5.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Localized Autoimmune Disease Diagnostics
      • 6.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.2. Multiple Sclerosis
        • 6.5.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.3. Type 1 Diabetes
        • 6.5.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.4. Hashimoto's Thyroiditis
        • 6.5.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.5. Idiopathic Thrombocytopenic Purpura
        • 6.5.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.6. Others
        • 6.5.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Allergy And Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Allergy and Autoimmune Disease Diagnostics Market: End Use Movement Analysis
  • 7.4. Allergy Diagnostics
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Hospitals & Clinics
      • 7.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Diagnostics Laboratories
      • 7.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Research Institutions
      • 7.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Autoimmune Diagnostics
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Hospitals & Clinics
      • 7.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Diagnostics Laboratories
      • 7.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Research Institutions
      • 7.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Others
      • 7.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Products and Services Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Thermo Fisher Scientific, Inc.
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Products and Services Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. HYCOR Biomedical
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Products and Services Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer)
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Products and Services Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Omega Diagnostics GROUP PLC
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Products and Services Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Lincoln Diagnostics, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Products and Services Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AESKU.GROUP GmbH
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Products and Services Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Minaris Medical America, Inc.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Products and Services Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. HOB Biotech Group Corp., Ltd.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Products and Services Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. DASIT Group SPA
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Products and Services Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. R-Biopharm AG
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Products and Services Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. BIOMERIEUX
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Products and Services Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Siemens Healthcare GmbH
      • 8.5.12.1. Company Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Products and Services Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Hoffmann-La Roche Ltd
      • 8.5.13.1. Company Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Products and Services Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. Abbott
      • 8.5.14.1. Company Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Products and Services Benchmarking
      • 8.5.14.4. Strategic Initiatives
    • 8.5.15. Beckman Coulter, Inc.
      • 8.5.15.1. Company Overview
      • 8.5.15.2. Financial Performance
      • 8.5.15.3. Products and Services Benchmarking
      • 8.5.15.4. Strategic Initiatives
    • 8.5.16. Danaher Corporation
      • 8.5.16.1. Company Overview
      • 8.5.16.2. Financial Performance
      • 8.5.16.3. Products and Services Benchmarking
      • 8.5.16.4. Strategic Initiatives
    • 8.5.17. Quest Diagnostics
      • 8.5.17.1. Company Overview
      • 8.5.17.2. Financial Performance
      • 8.5.17.3. Products and Services Benchmarking
      • 8.5.17.4. Strategic Initiatives
    • 8.5.18. Nova Diagnostics Pte Ltd.
      • 8.5.18.1. Company Overview
      • 8.5.18.2. Financial Performance
      • 8.5.18.3. Products and Services Benchmarking
      • 8.5.18.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Allergy and Autoimmune Disease Diagnostics Market, by products and services, 2021 - 2033 (USD Million)
  • Table 3 U.S. Allergy and Autoimmune Disease Diagnostics Market, by test type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Allergy and Autoimmune Disease Diagnostics Market, by diagnostics type, 2021 - 2033 (USD Million)
  • Table 5 U.S. Allergy and Autoimmune Disease Diagnostics Market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. allergy and autoimmune disease diagnostics market: Market outlook
  • Fig. 10 U.S. allergy and autoimmune disease diagnostics competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. allergy and autoimmune disease diagnostics market driver impact
  • Fig. 16 U.S. allergy and autoimmune disease diagnostics market restraint impact
  • Fig. 17 U.S. allergy and autoimmune disease diagnostics market strategic initiatives analysis
  • Fig. 18 U.S. allergy and autoimmune disease diagnostics market: Products and services movement analysis
  • Fig. 19 U.S. allergy and autoimmune disease diagnostics market: Products and services outlook and key takeaways
  • Fig. 20 Allergy diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Instruments market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Consumables market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Services market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Instruments market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Consumables market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Services market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. allergy and autoimmune disease diagnostics market: Test type movement analysis
  • Fig. 29 U.S. allergy and autoimmune disease diagnostics market: Test type outlook and key takeaways
  • Fig. 30 Allergy diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 In vivo test market estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Skin prick test market estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Intradermal test market estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Patch test market estimates, 2021 - 2033 (USD Million)
  • Fig. 35 In vitro test market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Autoimmune disease diagnostics test market estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Antinuclear antibody tests market estimates, 2021 - 2033 (USD Million)
  • Fig. 38 Autoantibody tests estimates, 2021 - 2033 (USD Million)
  • Fig. 39 C-reactive Protein (CRP) market estimates, 2021 - 2033 (USD Million)
  • Fig. 40 Complete Blood Count (CBC) market estimates, 2021 - 2033 (USD Million)
  • Fig. 41 Urinalysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 42 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 43 U.S. allergy and autoimmune disease diagnostics market: Diagnostics type movement analysis
  • Fig. 44 U.S. allergy and autoimmune disease diagnostics market: Diagnostics type outlook and key takeaways
  • Fig. 45 Allergy diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 46 Food market estimates, 2021 - 2033 (USD Million)
  • Fig. 47 Dairy products market estimates, 2021 - 2033 (USD Million)
  • Fig. 48 Poultry product market estimates, 2021 - 2033 (USD Million)
  • Fig. 49 Tree nuts market estimates, 2021 - 2033 (USD Million)
  • Fig. 50 Peanuts market estimates, 2021 - 2033 (USD Million)
  • Fig. 51 Shellfish market estimates, 2021 - 2033 (USD Million)
  • Fig. 52 Wheat market estimates, 2021 - 2033 (USD Million)
  • Fig. 53 Soys market estimates, 2021 - 2033 (USD Million)
  • Fig. 54 Other food allergens market estimates, 2021 - 2033 (USD Million)
  • Fig. 55 Inhaled market estimates, 2021 - 2033 (USD Million)
  • Fig. 56 Drug market estimates, 2021 - 2033 (USD Million)
  • Fig. 57 Other allergens market estimates, 2021 - 2033 (USD Million)
  • Fig. 58 Autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 59 Systemic autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 60 Rheumatoid arthritis market estimates, 2021 - 2033 (USD Million)
  • Fig. 61 Ankylosing spondylitis market estimates, 2021 - 2033 (USD Million)
  • Fig. 62 Systemic Lupus Erythematosus (SLE) market estimates, 2021 - 2033 (USD Million)
  • Fig. 63 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 64 Localized autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 65 Multiple sclerosis market estimates, 2021 - 2033 (USD Million)
  • Fig. 66 Type 1 diabetes market estimates, 2021 - 2033 (USD Million)
  • Fig. 67 Hashimoto's thyroiditis market estimates, 2021 - 2033 (USD Million)
  • Fig. 68 Idiopathic thrombocytopenic purpura market estimates, 2021 - 2033 (USD Million)
  • Fig. 69 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 70 U.S. allergy and autoimmune disease diagnostics market: End use movement analysis
  • Fig. 71 U.S. allergy and autoimmune disease diagnostics market: End use outlook and key takeaways
  • Fig. 72 Allergy Diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 73 Hospitals & clinics market estimates, 2021 - 2033 (USD Million)
  • Fig. 74 Diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 75 Research institutions market estimates, 2021 - 2033 (USD Million)
  • Fig. 76 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 77 Autoimmune diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 78 Hospitals & clinics market estimates, 2021 - 2033 (USD Million)
  • Fig. 79 Diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 80 Research institutions market estimates, 2021 - 2033 (USD Million)
  • Fig. 81 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 82 U.S. allergy and autoimmune disease diagnostics market share and leading players
  • Fig. 83 U.S. market share and leading players
  • Fig. 84 U.S. SWOT
  • Fig. 85 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 86 Market share of key market players- U.S. allergy and autoimmune disease diagnostics market